Keyphrases
Pharmacological Inhibitors
100%
Glioblastoma multiforme
100%
Cyclin-dependent Kinase 6 (CDK6)
100%
Intracranial Xenografts
100%
PD0332991
100%
Glioblastoma multiforme Cells
42%
Xenograft
14%
Molecular Targets
14%
Blood-brain Barrier
14%
Disease Progression
14%
Specific Inhibitor
14%
Molecular Determinants
14%
Survival Benefit
14%
Senescence
14%
Small Molecule Inhibitors
14%
Genetic Lesions
14%
Improved Survival
14%
Highly Effective
14%
Primary Determinants
14%
Potential Gains
14%
Short Hairpin RNA (shRNA)
14%
Temozolomide
14%
Newly Diagnosed Glioblastoma
14%
Radiation Therapy
14%
In Vitro Testing
14%
Initial Treatment
14%
In Vivo Response
14%
Retinoblastoma Protein
14%
Xenograft Tumor
14%
G1 Cell Cycle Arrest
14%
Recurrent Glioblastoma multiforme
14%
Clinical Trial Evaluation
14%
RNA Depletion
14%
Medicine and Dentistry
Glioblastoma
100%
Xenograft
100%
Cyclin-Dependent Kinase 4
100%
Cyclin-Dependent Kinase 6
100%
Glioblastoma Multiforme Cell Line
40%
Cell Line
40%
Retinoblastoma Protein
40%
Neoplasm
20%
Disease Exacerbation
20%
In Vitro
20%
Temozolomide
20%
Tumor Xenograft
20%
Short Hairpin RNA
20%
Blood Brain Barrier
20%
G1/S Transition
20%
Clinical Trial
20%
Radiation Therapy
20%
Neuroscience
Glioblastoma Multiforme
100%
Cyclin Dependent Kinase 4
100%
Cyclin Dependent Kinase 6
100%
Cell Line
57%
Retinoblastoma Protein
28%
In Vivo
14%
Small Hairpin RNA
14%
In Vitro
14%
Blood Brain Barrier
14%
G1 Phase Cell Cycle Checkpoint
14%
Temozolomide
14%
Radiation Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclin Dependent Kinase 4
100%
Glioblastoma
100%
Cyclin Dependent Kinase 6
100%
Neoplasm
28%
Retinoblastoma Protein
28%
Molecular Target
14%
Clinical Trial
14%
Disease Exacerbation
14%
Temozolomide
14%
Short Hairpin RNA
14%
Blood-Brain Barrier
14%